Your Guide to Natural Healing

Treating Cancer Without Injury


Physician Reference
Product Guide
Donate to keep this site alive
Wellness Events

Alternative Medicine:
A Comparison

FDA World: 1965-2008
A tiny peek into the mind of the FDA

Can Environment Affect Your Health?

Vaccines: The Whole Truth And Nothing But

What is Your Prescription Medication Doing To You?

Timing Increases Effects of Supplements, Drugs and Surgery

The Brain-Gut Connection

Minerals and Their Function

Check Your Digestion

Who is Angel?



Update 7/29/12:  This article was written in 2002.  Poly MVA has since taken hold and you can read about Dr. James Forsythe, MD, HMD, board certified oncologist, who started the Cancer Wards at each of the 3 major Nevada hospitals and ran the Cancer Program at the VA Medical Center, discuss this remarkable substance.

Following is a description of a patented compound called Polydox or Poly-MVA which appears to meet the criteria of being non-toxic to normal cells yet lethal to malignant ones.

Tumor Cell Specific Killing

In 1931, Otto Warburg was awarded a Nobel Prize for being the first to identify respiratory enzymes and discovering that cancer cell respiration was glycolytic instead of oxygen dependent. He found that cancer development caused a major change in energy metabolism.

Based on Warbrug's findings, in 1995, Merrill Garnett was issued a patent for a novel cancer chemotherapeutic agent which attacks a target which is only found in malignant cells and is related to specific changes in energy metabolism. This compound has been named Polydox (U.S. trials) or Poly-MVA (Canada & Mexico) or LAPd by some researchers. The MVA stands for minerals, vitamins and aminoacids. LAPd stands for Lipoic Acid / Palladium complex.

Cancer is now considered a systematic, as opposed to a local, disease and its cause is multifactorial. Poly MVA attacks one of the root causes of cancer. It is a complex of lipoic acid, palladium, B12 and other B complex vitamins connected to a metal substrate. The complex is very soluble in water and fat. Therefore it travels all over the body and into every cell. It is classified as a nucleotide reductase.

Paul M. Bingham of State University of New York's Department of Biochemistry and Cell Biology clearly demonstrated from a molecular and cell biological perspective the anti-tumor activity of Poly MVA. Other therapeutic benefits from these compounds are related to the effect on the body systems of the antioxidant power of the Lipoic acid and the known benefits of B-12 and the other B vitamins. These have been reported as increased energy, improved appetite and pain control measured by reduction of the need for pain medication.

Animal Studies

Pharmakon Laboratories performed nude mouse studies using glioblastoma cell line and the PolyMVA. On day 0, tumor cells were injected subcutaneously in the scruff of the neck of Swiss-nude mice. When the tumors reached 200 to 400 mm in volume, the mice were divided into 8 groups of 10 mice. Four groups were dosed daily I.V., and four groups were dosed daily IP, with either vehicle or test article at 1.5, 1, or 2 mg/mouse. Mice were dosed for 4 weeks. The volume of each tumor was determined twice per week.

Necropsies were performed on all animals at termination of study or when they were found dead. A reduction in tumor size compared to the vehicle treated group was seen in all groups. This reduction was statistically significant in the orally treated when the dose was 1 mg/mouse. It was significant in all the intravenous treated group.

Summary: Based on the data from this study this synthetic reductase administered orally at 1 mg/mouse or IV at 0.5, 1 or 2 mg/mouse significantly reduced the growth of the glioblastom tumor cell line in nude mice.

Clinical Studies

The first report of clinical studies of PolyMVA was presented by the late Rudolf E. Falk, an oncological surgeon at the University of Toronto, in March 1994. Dr. Falk reported that the compound was administered intravenously, subcutaneously (under the skin) and per Os in a modified phase 2 study. To quote from Dr. Falk's summary, "95 patients were treated; these included breast, lung, colorectal, prostate, pancreatic, ovarian, malignant melanoma and primary brain neoplasia. 90% of the patients were in the category of having failed all available therapy. 88 are surviving on therapy with a mean survival time of 9 months. The anticipated survival time of this group, from available statistics would vary from 20% to 60% at 6 months. All of these patients received moderate doses of chemotherapy."

The first 27 patients given PolyMVA were all considered terminal, and all refused to continue with chemotherapy. They were placed on a "health promotion program" as outlined in The Definitive Guide to Cancer, Chapter 23. The cancers involved brain, tongue, esophagus, lung, breast, stomach, colon, pancreas, prostate, lymph, blood, and marrow. All had metastasis. All were given 5 drops four times daily as a loading dose. 13 reported improvements in either appetite, weight gain, increased energy or reduction in pain within the first 7 days of starting PolyMVA. At the end of 14 days 6 additional patients reported improvement. None of the 27 patients reported adverse reactions.

We learned from this small study (1) that the initiating dose was inadequate, (2) rapid improvements can be expected in over 60% of patients with a variety of malignant conditions, and (3) PolyMVA is non-toxic. With this low dose, some patients demonstrated clinical changes indicating early improvement. A few anecdotal reports follow:

75 year old female with glioblastoma presented with history of debulking surgeries and 2 rounds of radiation. As a last resort her cancer center neurologist placed her on massive, experimental doses of tomoxifen. She entered the hospital in Baja California requiring support on both arms to walk up the short ramp. Her memory was impaired, she had slurred speech. Convulsions were under control with dilantin. On the 3rd day after beginning PolyMVA her memory had improved as had her slurred speech. She walked out of the hospital unaided to continue therapy at home. She lived 6 months. Her immediate death is attributable to the side effects of the tamoxifen which she continued to take before and after the PolyMVA.

Glioblastoma patients usually have a dramatic, early response similar to Mr. D. age 66. His tumor inactivated his right leg and foot and caused generalized convulsions which were poorly controlled by tegretol, or dilantin. I received a phone call from Mr. D. four days after he began PolyMVA. He said his paralysis was gone and he could walk outside and water the lawn and ride his stationary bicycle. Eight days after beginning he called again to report that his convulsions were now localized and almost gone.

Pain from metastatic breast cancer to the spine and right hip in CF age 56 required a right hip replacement which gave relief from hip pain, but did not effect the spine. She started PolyMVA and within 2 weeks her "back pain stopped" and she returned to her legal research employment. Most breast cancer patients report at least temporary improvement.

Two cases of cancer of esophagus requiring MS for pain relief, cachectic and terminal when they started PolyMVA. Mr. G. age 62 was in a Mexican hospital when he was scheduled to began the PolyMVA. LS age 45 took the PolyMVA for home use. Mr. G died within 6 weeks, but an investigation uncovered the fact hat he was never given the PolyMVA. He was given Laetril alone. LS reported increased strength and weight gain and is still living (2 years from starting PolyMVA).

Diagnosed in April 1995 a female multiple myeloma patient from Alaska with two degrees, a Ph.D. and J.D. sent us a letter dated March 1997 that after taking PolyMVA her blood tests and examinations showed " no measurable signs of multiple myeloma carcinoma" and her doctors said "She is in total remission."

Colon cancer patients with obstruction reported improvement using the PolyMVA by enema. This is logical since PolyMVA is soluable in fat and liquid.


The current scientific studies for the cure of cancer using destructive methods has not been entirely successful and should be supplemented with health supporting therapeutics and individual response reports (anecdotal data).

These studies indicate that no patient should be consigned to a "terminal classification" until no improvement is measured after a trial with PolyMVA and other health supporting measures. 

Successful individual outcomes using the new paradigm of health support versus cancer cell destruction are reported.  A new cancer compound which exclusively kills cancer cells based upon Warburg's cancer cell respiration physiology was discussed. There is an overwhelming need for studies using PolyMVA in stages one and two malignancies with and without destructive methods. See note below.

Who Developed it and what it can do for you?

When Albert Sanchez, Orange County school principal, vowed to his dying wife to relentlessly search for a cure for cancer, he never expected to find it. His sometimes frightening but eventful life finally led him to PolyMVA, a non-toxic antioxidant composed of alpha lipoic acid and palladium. This super nutrient, developed in the U.S. by Dr. M. Garnett, the discoverer of the 2nd Genetic Code, has already shown extraordinary healing abilities for degenerative diseases, including cancer.

Dr. Sanchez, CEO of several international pharmaceutical companies, shares with us his dream of finding a cure to life-threatening disease in his plan of creating a free University Hospital for the study of cancer. His wish to explain what this discovery offers and why doctors and veterinarians across the world are already using this product has led him to the podium of many lecture halls

Dr. Albert Sanchez has been focused on sharing information about the super antioxidant PolyMVA ever since realizing its significance. He is the author of several books and an accomplished speaker. He's available for daily phone interviews, for advice or to answer any of your questions. Telephone: (619) 656-1980


Also see:  Chinese Herb Triumphs Over CANCER + The Link between CANCER and Blood Type + 

Prostate CANCER: Facts You Should Know + several CANCER articles on the Index page below.

NOTE: Before PolyMVA, the father of alternative medicine in Germany, Dr. Josef Issels, reported 18.5% of the terminal patients he treated lived 5 years or longer. There are many Alternative Physicians in the United States achieving similar results. Issels' treatments were health supporting as opposed to the current cancer destructive methods. Our use with PolyMVA has been limited to three years. In almost all cancers where the product was used the patients reported symptom improvement. More studies are necessary to assess the extent it prolongs life. PolyMVA can be used as an adjuvant to cancer destruction methods with great benefit to the patient. But for best results it is used with other health supporting regimens.

For further understanding of how the oxidation-reduction reactions and the hydrogen donor mechanisms provided by PolyMVA work, please refer to Understanding the Redox (rHS) Measurement of the Biological Terrain by Robert C. Greenberg. TLfDP Aug-Sept 1997. P. 64-68


For more interesting articles, click here for free access
to your guide to hard-to-find wellness information for obscure and difficult health conditions.


Health and Wellness Through Education